[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100123330":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":29,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Lahey Clinic","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"1",null,"Bladder Cancer Group:\n\nPatients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue.\n\nTwo urine samples collected at the time of the scheduled procedure:\n\nOne sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection.",{"label":13,"type":10,"description":14,"interventionNames":10},"2","Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.",[16],{"name":17,"affiliation":18,"role":19},"Kimberly Rieger-Christ, PhD","Lahey Clinic, Inc.","PRINCIPAL_INVESTIGATOR",[21,25],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},"CONTACT","781-744-2969","Kimberly.R.Christ@lahey.org",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Linda M. Topjian","781-744-8711","Linda.M.Topjian@Lahey.org",[30],{"facility":18,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Burlington","Massachusetts","01805","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-71.19561,42.50482,{"lat":41,"lon":40},[44,47,49,51],{"name":45,"role":46,"phone":10,"phoneExt":10,"email":10},"Arthur Mourtzinos, M.D.","SUB_INVESTIGATOR",{"name":48,"role":46,"phone":10,"phoneExt":10,"email":10},"Andrea Sorcini, M.D.",{"name":50,"role":46,"phone":10,"phoneExt":10,"email":10},"Ali Moinzadeh, M.D.",{"name":52,"role":46,"phone":10,"phoneExt":10,"email":10},"David Canes, M.D.",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100123330","evaluation-of-non-invasive-assays-for-the-detection-of-urothelial-cancer-100123330",false,"NCT00872495","Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer","Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney","Inclusion Criteria:\n\n* Patients scheduled to have a nephroureterectomy, cystectomy, cytoscopy (newly diagnosed bladder cancer and those with recurrent disease in follow up)\n* Control Group: No known evidence of bladder cancer-one urine sample\n* \\> than 18 years of age\n\nExclusion Criteria:\n\n* \\\u003C than 18 years of age",true,"ALL","18 Years",{"count":66,"type":67},500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to determine if analysis of DNA and protein material found in urine will be useful in the detection of urothelial cancer of the bladder and kidney. This analysis may be helpful to determine if how a particular cancer will act regarding remission and recurrence",[71,72,73,74],"Urothelial Cancer","Cancer","Bladder Neoplasms","Urinary Bladder Cancer",[71,72,73,74],"2025-12-01",{"date":78,"type":79},"2025-12-08","ACTUAL",{"date":81,"type":10},"2002-09",{"date":83,"type":67},"2028-11",{"name":5,"class":6},1]